Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2017

Chwee Teck Lim's Biography



Chwee Teck Lim, Provost's Chair Professor, Principal Investigator, Mechanobiology Institute, National University of Singapore

Professor Lim is Provost’s Chair Professor at the Department of Biomedical Engineering at the National University of Singapore. His research interests include the mechanobiology of human diseases and the development of microfluidic technologies for disease detection, diagnosis and therapy. He has authored more than 300 peer-reviewed papers (including 43 invited/review articles) and delivered more than 290 invited talks. He is an elected Fellow of the American Institute for Medical and Biological Engineering as well as an elected member of the World Council of Biomechanics. He currently sits on the editorial boards of 13 international journals. Prof Lim co-founded four startups which are commercializing technologies developed in his lab. He and his team have garnered more than 50 research awards and honors including the Asian Scientist 100 (2016), University’s Outstanding Researcher and Outstanding Innovator Awards (2014), the Credit Suisse Technopreneur of the Year Award, Wall Street Journal Asian Innovation Award (Gold) and the Asian Entrepreneurship Award (First Prize) (2012), President's Technology Award (2011) and the IES Prestigious Engineering Achievement Award (2010).

Chwee Teck Lim Image

Microfluidic Enrichment for Single Cancer Cell Analysis

Monday, 20 March 2017 at 16:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Tumor heterogeneity is currently a major hindrance to cancer diagnosis and treatment. Here, microfluidic technology is used to enrich and enable probing of the molecular heterogeneity of single circulating tumor cells so as to obtain patient derived information for the personalized treatment of cancer patients.

Tumor heterogeneity is a general trait of cancer which has proven to be a major hindrance in cancer classification, diagnosis and treatment. Cancer can be classified loosely into a few distinct sub-types, but recent technological advances have begun to reveal the true extent of its heterogeneity. Single cell analysis is emerging as an important approach to detect variations in morphology or genetic, proteomic and molecular expression.  Here, we will present several novel microfluidic technologies to probe the heterogeneity of cancer patient derived circulating tumor cells (CTCs).  These include detecting the proteolytic capability of each CTC to obtain hint of their invasiveness as well as identify unique actionable key driver mutations with aim of improving anticancer therapy.  It is hope that this single cell analysis approach will not only lead to more precised treatment of cancer patients from the individually derived information of these tumor cells, but will also aid in the development of better drugs to combat this disease.

Microfluidic Enrichment for Single Cancer Cell Analysis

Monday, 20 March 2017 at 16:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Tumor heterogeneity is currently a major hindrance to cancer diagnosis and treatment. Here, microfluidic technology is used to enrich and enable probing of the molecular heterogeneity of single circulating tumor cells so as to obtain patient derived information for the personalized treatment of cancer patients.

Tumor heterogeneity is a general trait of cancer which has proven to be a major hindrance in cancer classification, diagnosis and treatment. Cancer can be classified loosely into a few distinct sub-types, but recent technological advances have begun to reveal the true extent of its heterogeneity. Single cell analysis is emerging as an important approach to detect variations in morphology or genetic, proteomic and molecular expression.  Here, we will present several novel microfluidic technologies to probe the heterogeneity of cancer patient derived circulating tumor cells (CTCs).  These include detecting the proteolytic capability of each CTC to obtain hint of their invasiveness as well as identify unique actionable key driver mutations with aim of improving anticancer therapy.  It is hope that this single cell analysis approach will not only lead to more precised treatment of cancer patients from the individually derived information of these tumor cells, but will also aid in the development of better drugs to combat this disease.


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers World Congress 2017Circulating Biomarkers World Congress 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com